A cost-effectiveness analysis of provider and community interventions to improve the treatment of uncomplicated malaria in Nigeria: study protocol for a randomized controlled trial by Virginia Wiseman et al.
TRIALS
Wiseman et al. Trials 2012, 13:81
http://www.trialsjournal.com/content/13/1/81STUDY PROTOCOL Open AccessA cost-effectiveness analysis of provider and
community interventions to improve the
treatment of uncomplicated malaria in Nigeria:
study protocol for a randomized controlled trial
Virginia Wiseman1*, Ogochukwu Ezeoke2, Emmanuel Nwala2, Lindsay J Mangham1, Bonnie Cundill3,
Jane Enemuo2, Eloka Uchegbu2, Benjamin Uzochukwu2 and Obinna Onwujekwe2Abstract
Background: There is mounting evidence of poor adherence by health service personnel to clinical guidelines for
malaria following a symptomatic diagnosis. In response to this, the World Health Organization (WHO) recommends
that in all settings clinical suspicion of malaria should be confirmed by parasitological diagnosis using microscopy
or Rapid Diagnostic Test (RDT). The Government of Nigeria plans to introduce RDTs in public health facilities over
the coming year. In this context, we will evaluate the effectiveness and cost-effectiveness of two interventions
designed to support the roll-out of RDTs and improve the rational use of ACTs. It is feared that without supporting
interventions, non-adherence will remain a serious impediment to implementing malaria treatment guidelines.
Methods/design: A three-arm stratified cluster randomized trial is used to compare the effectiveness and cost-
effectiveness of: (1) provider malaria training intervention versus expected standard practice in malaria diagnosis
and treatment; (2) provider malaria training intervention plus school-based intervention versus expected standard
practice; and (3) the combined provider plus school-based intervention versus provider intervention alone. RDTs will
be introduced in all arms of the trial. The primary outcome is the proportion of patients attending facilities that
report a fever or suspected malaria and receive treatment according to malaria guidelines. This will be measured by
surveying patients (or caregivers) as they exit primary health centers, pharmacies, and patent medicine dealers.
Cost-effectiveness will be presented in terms of the primary outcome and a range of secondary outcomes,
including changes in provider and community knowledge. Costs will be estimated from both a societal and
provider perspective using standard economic evaluation methodologies.
Trial registration: Clinicaltrials.gov NCT01350752
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Rationale for the study
In 2001, as a response to increasing levels of resistance to
antimalarial medicines, the World Health Organization
(WHO) recommended that all countries experiencing re-
sistance to conventional monotherapies should use com-
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reproduction in any medium, provided the orderivatives (artemisinin-based combination therapies
(ACTs)) for the treatment of uncomplicated P. falciparum
malaria [1,2].
The switch to ACTs raises a number of challenges not
least of which is their relatively high cost. For many
countries, ACTs are as much as 10 times the price of
most monotherapies [3-5]. Combined with the fact that
clinical diagnosis may result in over-diagnosis because
the signs and symptoms of malaria are non-specific and
therefore overlap with other febrile diseases [6], then
‘the relatively high cost of ACTs makes waste throughal Ltd This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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unsustainable’ [7].
This has led to growing pressure to improve the speci-
ficity of malaria diagnosis. In 2010, the WHO released a
second edition of Guidelines for the Treatment of Mal-
aria in which it recommends parasitological confirm-
ation of suspected malaria cases in all patients before
treatment where testing facilities are available [8]. In
addition to securing cost savings, it is argued that para-
sitological diagnosis: improves patient care in parasite-
positive patients owing to greater certainty that the pa-
tient has malaria; helps to identify parasite-negative
patients in whom another diagnosis must be sought; pre-
vents unnecessary exposure to antimalarials, thereby re-
ducing side-effects, drug interactions, and selection
pressure; improves health information; and confirms
treatment failures [7].
Two methods for parasitological testing of malaria are
microscopy and Rapid Diagnostic Tests (RDTs). While
microscopy has been the gold standard, a number of
strong arguments have been put forward in favor of
RDTs. RDTs have the potential to provide accurate and
timely diagnosis to those previously unable to access
good quality microscopy services [4,8-11]. They are rela-
tively simple to use and do not require specialized skills
[12,13] compared to microscopy, which is labor-inten-
sive and time-consuming [9]. They do not require
laboratory equipment and reagents that are often
unavailable in remote locations or resource-poor
settings [11].
According to the WHO, the move towards universal
diagnostic testing of malaria is a critical step forward in
the fight against malaria as it will allow for the targeted
use of ACTs for those who actually have malaria. In
practice however, studies suggest that there are persist-
ent barriers to universal testing. A distrust of test results
particularly negative ones [14-16], lack of alternative
drugs with which to treat fever patients [17,18], and pa-
tient demand for inappropriate medicines [17,19-21] are
some of the factors shown to influence whether a mal-
aria test is done and in turn, acted upon.
Our own formative research in Nigeria has also
revealed barriers to the effective implementation of mal-
aria treatment guidelines [19]. Between May 2009 and
June 2010 using cross-sectional cluster surveys with
patients and providers, and a series of focus group dis-
cussions, it was shown that very few facilities had mal-
aria testing available; no medicine retailers and only 13%
of public facilities had microscopy available and none
had RDTs. Despite ACTs becoming the recommended
treatment for uncomplicated malaria in Nigeria in 2005,
they remain underused. Approximately 80% of health fa-
cilities (including medicine retailers) had ACTs in stock
at the time of the survey but only 55% of providers (bywhich we mean health workers) knew that ACTs are the
recommended treatment. ACTs were received by only
22% of fever cases treated at health facilities, and were
often received in the wrong dose (34%). Sulfadoxine-pyr-
imenthamine (SP) is no longer recommended for treat-
ing malaria but was still frequently used with just over
one-third of patients receiving this medicine. Our re-
search also highlighted the importance of patient
demand in influencing the treatment received. Approxi-
mately 55% of patients surveyed requested a specific
medicine and in most cases this was not the nationally
recommended treatment. Providers appear to be influ-
enced by what they perceive patients to want or are able
to afford. There was also considerable skepticism among
patients and caregivers about negative test results, high-
lighting the need for greater awareness of alternative
causes of febrile illness.
These findings reinforce the need to ensure that the
large-scale roll-out of RDTs in Nigeria is accompanied
by interventions that encourage providers to deliver
treatment consistent with guidelines. While there have
been several evaluations assessing whether the intro-
duction of RDTs will be cost-effective compared to
both presumptive treatment and to field microscopy
[4,22-24], surprisingly little evidence exists about the
cost-effectiveness of training interventions to support
the large scale roll-out of RDTs [25]. This study will use
a cluster randomized design, in public facilities and
medicine retailers, to compare the cost-effectiveness of a
provider training intervention and a combined provider
training and school-based malaria intervention to
expected standard practice of supplying RDTs with a
demonstration on how to use them. The overall aim is
to assist Nigerian policymakers in their pursuit of deli-
vering maximum health benefits and value for money in
malaria control.
Methods/design
The interventions will be evaluated using a three-arm
stratified, cluster randomized trial across 42 clusters,
14 clusters per arm, in two areas in Nigeria. Since
the school-based intervention is being delivered at the
community level a cluster is defined as a geographical
community which contains at least one facility and
one school, and this will be the unit of randomization
with study site (urban-rural setting) as the stratum.
Clusters will be selected at random within each
stratum with the number per stratum selected prob-
ability proportional to size. Due to logistics and costs,
a total of 138 health facilities and 38 schools will be
included in the study. Schools and facilities will be
randomly selected from within each cluster to receive
the cluster intervention. Up to three schools per clus-
ter will be randomly selected from a list of schools
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of the Ministry of Education Enugu State, while the
number of facilities per cluster will be selected prob-
ability proportional to size. Communities will be ran-
domized to one of the following three arms:
 Arm 1 (expected standard practice): Facilities invited to supply RDTs
 Demonstration on how to use RDTs
 Arm 2
 Facilities invited to supply RDTs
 Provider intervention: training and supervision
on malaria diagnosis and treatment (which
includes a demonstration on how to use RDTs)
 Arm 3
 Facilities invited to supply RDTs
 Provider intervention: training and supervision
on malaria diagnosis and treatment (which
includes a demonstration on how to use RDTs)
 School-based malaria education intervention.
The first arm represents expected standard practice
when RDTs are introduced in public health facilities and
medicine retailers. This is the approach most likely to be
adopted by the State Malaria Control Programme and
the Association of Community Pharmacists and Associ-
ation of PMDs in the near future. All of these organiza-
tions have been involved in the design of the
interventions. To date, only a small quantity of RDTs
has been distributed with basic training to public health
facilities in Nigeria. None have been distributed to facil-
ities taking part in this study.
Outcomes will be assessed through exit interviews
with patients as well as provider surveys and household
surveys. Economic and financial costs will also be mea-
sured to enable the calculation of incremental cost-ef-
fectiveness ratios. Ethical approval for this study has
been obtained from the University of Nigeria and the
London School of Hygiene and Tropical Medicine.
Study area
The study is being conducted in two sites in Enugu State
in south-eastern Nigeria. Enugu state is geographically
located in the southern zone of Nigeria between 7°10′N
and 7°45′N of the Equator and on longitude of 7.4878°E
and latitude of 6.4231°N. It is bordered on the north by
Kogi and Benue States and on the south by Abia and
Imo States, on the east by Ebonyi State, and on the west
by Anambra State. The bioclimatic zone is rainforest innature with annual rainfall between 152 cm and 203 cm
and temperature ranges from 22.2°C to 30.6°C. The state
has a land area of 7,617.82 km2 and a population of
3,289,589 people. The activities of the majority of the
population include farming, fishing, wine tapping, and
poultry keeping and rearing of domestic animals. The
main occupation which is farming runs from November
to February. The people of Enugu are of Igbo ethnicity
and speak the Igbo language.
The two sites are Enugu Urban (comprising of Enugu
East, Enugu South, and Enugu North) and Udi Local
Government Areas (LGA). Enugu Urban is the largest
predominantly urban area in Enugu State and contains a
population of 722,664 (National Bureau of Statistics:
www.nigerianstat.gov.ng). However, about 30% of Enugu
East LGA is rural. The Udi study site lies to the west of
Enugu and is predominantly rural. The population of the
Udi LGA is estimated to be 234,002 (National Bureau of
Statistics: www.nigerianstat.gov.ng). The land mass of
Udi LGA is more than that of the combined three com-
ponent LGAs of Enugu Urban.
Malaria is endemic in Enugu state, and occurs all year
round. Research in the study area shows that patent
medicine dealers (PMDs, also known as patent medicine
vendors) are the major source of treatment for malaria
[26-29]. These studies also show that chloroquine, SP,
and artesunate monotherapy are still provided and con-
sumed for the treatment of malaria.
The study sites are similar in terms of language and
culture but differ in terms of number of health facilities,
due to the rural nature of Udi LGA, which has fewer
public facilities and pharmacies while the reverse is the
case in Enugu which is predominantly urban.
The communities are autonomous and all have a trad-
itional ruler. Hence, a distinct community will have a
traditional ruler and in some cases, a town union execu-
tive council. Most communities are comprised of com-
ponent villages and the numbers of villages in a
community depends on the size of the community. Each
village is in turn comprised of super-family units that
trace their origin to a common progenitor. The super-
family units are made up of a number of households. All
communities have at least one primary school and most
have a secondary school.
Participants
Interviewers will explain to all participants that involve-
ment in the study is voluntary and they have the right to
withdraw at any point in time and to ask any questions.
Information about the study will be read to all partici-
pants and provided in hard copy. All consenting partici-
pants will be asked to sign two standard consent forms
(that is one for the patient to take home and one
retained by the interviewer).
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Two types of healthcare facilities are included in the
study: public primary health facilities and medicine retai-
lers (including private pharmacies and private PMDs).
Public primary health facilities include primary health
centers, dispensaries, and health posts. They are
expected to provide healthcare services for the preven-
tion and treatment of common endemic diseases. There
are rarely laboratory services at this level. Nurses, senior
and junior community health extension workers
(CHEWS), work at these facilities. There are often no
doctors, but in some cases there are visiting doctors.
Most of the pharmacy shops are located in the urban
area though a few are found in rural areas. PMDs are
found in both urban and rural areas. There are regula-
tory bodies governing them namely the Pharmaceutical
Association of Nigeria and Association of Patent Medi-
cine Dealers, respectively. The State Ministry of Health
has general oversight. Pharmacies and PMDs are
licensed to sell over-the-counter drugs only. PMDs are
retail outlets for drugs but also act as de-facto service
providers.
To obtain a license, pharmacy shops are required to
have at least one qualified pharmacist. In contrast,
PMDs do not require any form of special training or
qualification to obtain their license. Most of these pri-
vate facilities obtain their drug supplies through both
formal and informal channels including large retail and
wholesale pharmacies in major cities, direct from
pharmaceutical companies, and through visiting com-
pany representatives, a number of them from the open
market.
All public facilities and medicine retailers in eligible
clusters will be enumerated and facilities informed of the
proposed study. Facilities will be selected at random and
asked to provide written consent prior to cluster
randomization. Where facility-level consent is not pro-
vided, replacement facilities will be randomly selected
from the remaining list of eligible facilities. All providers
responsible for diagnosis and treatment of suspected
cases of malaria are eligible to participate in the provider
survey and asked to provide written consent.
Patients/caregivers
All patients (or their caregiver) attending the health fa-
cilities and medicine retailers will be approached on exit
for consent to participate in an exit survey and screened
for their eligibility. Patients will be eligible if they are
present at the facility and they (or their caregiver) report
seeking treatment for fever or suspected malaria.
Patients will be excluded if they are pregnant, less than
6 months old, or have signs and symptoms of severe
malaria. The household survey will be administered with
a household member (usually the mother as the maincaregiver) and she (or he) will be asked about their
knowledge and preferences relating to malaria diagnosis
and treatment and also details of any treatment seeking
in the past 2 weeks.
Schools
Primary and secondary schools in the study clusters will
be eligible to take part in the study. There are a total of
67 secondary schools in both Enugu urban and Udi (that
is 45 in Enugu Urban and 22 in Udi) and 247 primary
schools in both Enugu Urban and Udi (that is 156 in
Enugu Urban and 91 in Udi). On average, there are ap-
proximately three schools per community and virtually
every community has a primary and a secondary school.
In Enugu urban, some of these schools are in the same
compound, bearing a similar name but differentiated by
numbering (such as I, II, III, IV) and managed by differ-
ent administrators commonly known as ‘head teacher’ in
primary schools and ‘principal’ in secondary schools. For
the purposes of this study schools within the same com-
pound were considered as a single school in the selec-
tion process. This compound characteristic of the urban
schools is not same in Udi as the schools are widely
spread often located in different villages within the same
community/intervention cluster.
Consenting schools will be invited to participate in a
range of activities designed to raise awareness about
diagnosing malaria using RDTs and that ACTs are the
recommended antimalarial. With support from the re-
search team, the head teachers and school principals
with their deputies will oversee the intervention in
their schools. In compound schools administrators for
each school within the compound will oversee the
intervention.
Interventions
Intervention activities for this study will be: facilities
invited to supply RDTs; demonstration on how to use
RDTs; provider training and supervision; and school-
based intervention.
Facilities invited to supply RDTs
RDTs for diagnosing malaria will be made available to all
health facilities that participate in the study and attend
the demonstration by the research team on how to use
RDTs. The RDT that will be provided is SD Bioline Mal-
aria Ag Pf, which was chosen in conjunction with the
States Malaria Control Programme, and is reported to
have a minimum detection rate for P. falciparum
of 97.5% even at low levels of parasitaemia (200 para-
sites/μL) [30].
Estimates of RDTs required at each facility will be
determined in discussion with the facility head and
based on routine records for the number of febrile
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into account seasonal variations) as well as data gathered
during the formative research. The research team will
procure adequate quantities of RDT kits to last through-
out the evaluation phase. The project will also be re-
sponsible for distributing the RDTs to health facilities.
Facilities will be able to request stocks from the research
team when they run out or collect them from the re-
search team’s office. Stock management records will be
kept by the research team to monitor the distribution of
RDTs. The RDT kits will be stamped for identification
and facilities will be advised to store them in a cool, dry
place. The research team has developed a commodity
tracking system involving the use of stock issuing and
stock receiving vouchers to keep track of the kits so they
know when there is likely to be a stock-out.
Currently, the state government advises that RDTs
should be available without charge in primary health
centers for pregnant women and children under 5 years
old. Hence, the project will not charge any fee for RDTs
in the public sector. However, RDTs will be distributed
to providers of private facilities at a subsidized cost of 50
Naira (US$0.3) per testa. Facilities are asked not to sell
kits beyond 100 (US$0.6) to their clients so that the test
can remain affordable. These facilities will reimburse the
study team when they finish using the test kits. The
study team will not supply ACTs to health facilities.
Demonstration on how to use RDTs
Providers will be invited to attend a demonstration on
how to use RDTs. This is to ensure that providers are
shown the steps involved in using the RDT and the im-
portant safety procedures, such as wearing gloves when
conducting the test, how to prick a finger to get a sam-
ple of blood, and safe storage and disposal of the used
materials. The demonstration will include a practical ex-
ercise in which the providers will each conduct a test,
under observation. Participants will also receive a copy
of the WHO job aid which shows the steps in using an
RDT. The demonstration will be conducted by the Re-
search Team in collaboration with the State Malaria
Control Programme.
Provider training intervention (including support visits)
In addition to the supply of RDTs and the demonstration
of how to use RDTs, facilities in clusters randomized to
arms 2 and 3 will receive additional provider training
and support visits. Provider training on malaria diagnosis
and treatment will be conducted over 2 days and con-
tains six training modules on: (1) Knowledge on malaria;
(2) Introduction of the updated guidelines for malaria
diagnosis and treatment; (3) Appropriate diagnosis;
(4) Appropriate treatment when test is positive; (5) Ap-
propriate treatment when test is negative; and (6)Effective communication. Together these training mod-
ules will improve providers’ knowledge and skills on why
it is important to test for malaria, how to use a RDT,
and the effective implementation of clinical guidelines.
The first module describes the current burden of malaria
in Nigeria, in addition to its causes, signs, and symp-
toms. The second module reviews the clinical guidelines
and highlights the importance of malaria testing in fe-
brile patients before treatment is prescribed. The module
on appropriate diagnosis includes a practical session in
which all providers will get hands-on experience of the
steps involved in using an RDT. This is equivalent to the
intervention ‘demonstration on how to use RDTs’ that is
delivered to participants in Arm 1. Module 4 provides
training on what treatment to give when a test is posi-
tive, the recommended types of antimalarial drugs, in-
cluding the dosage regimens for different age groups
and types of ACT. Module 5 provides advice on other
causes of febrile illness which should be investigated if
the malaria test is negative. The objective of the last
module on communication is to improve health provider
knowledge of the importance of patient communication
and barriers to effective communication. Providers will
learn how to discuss different treatment options with
patients especially when the test result is negative.
Training will be conducted in different venues depend-
ing on the study site. In Enugu, the Laboratory of the
Department of Pharmacology and Therapeutics, College
of Medicine, University of Nigeria Enugu will be the
venue. In Udi, the district hospital conference center
and local government area headquarters hall will be
used. The following types of providers will be invited to
the training: in the public facilities, the officer in charge
and one other health worker who is involved in prescrib-
ing treatment; and in the private, the head of the facility
or whoever s/he appoints. It is anticipated that two pro-
viders from each public facility and one from each pri-
vate facility will attend. The training will be conducted
by eight people from the research team and four people
from the state malaria control programme. The trainers
will receive extensive briefing by the research team and
be given a trainers’ manual in addition to the partici-
pants’ manual which provides details of the material for
each module and how it should be delivered.
Each training workshop will aim to train 20 to 25 pro-
viders. The training primarily takes a seminar style in
which the trainer delivers the training material, though
there will be discussions, practical sessions, and question
and answer sessions using short case scenarios. A parti-
cipants training manual will be given to providers that
attend the training course and this includes all essential
reference material such as the malaria treatment guide-
lines. Participants will also be provided with job aides on
how to perform RDTs, a treatment algorithm which can
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categories of nationally recommended drugs for the
treatment of malaria, their generic names, and dosage
regimens. While not enforced, all participants of the
provider training will be strongly encouraged to train
others who are involved in malaria treatment at their
facilities.
Members of the research team will provide support
visits to each facility every month during the implemen-
tation phase (3 months) and the subsequent evaluation
phase (approximately 2 months) to monitor and assess
what they are doing and to reinforce the skills acquired
by providers during the earlier training workshops. Dur-
ing the support visits, where possible, providers will be
observed delivering treatment to patients who have
sought treatment for fever, and questions on the differ-
ent aspects of the training will also be asked. Based on
the responses, guidance will be provided on areas where
the provider is experiencing difficulty. Providers will also
be asked about any challenges implementing what they
were taught during the training.
School-based intervention
This intervention will be implemented in selected pri-
mary and secondary schools in communities randomized
to arm 3. Peer health education has been shown to influ-
ence the knowledge, attitudes, and practice of school
children and their families as well as the wider commu-
nity [31]. In Enugu State, school-based health education
helped to improve community awareness and participa-
tion in onchocerciasis control activities [32-34]. In
Ghana [35], Lao PDR [36], and Thailand [37], school-
based malaria interventions have also been shown to im-
prove overall control of malaria within the communities
where the schools were located.
One of the documented advantages of school-based
interventions is their ability to reach a relatively large
proportion of any given community [38]. The reach of a
school-based intervention in Nigeria is expected to be
comparable. About 75% of households have school-aged
children (either their direct children or wards) and about
44% of school-aged children (6–17 years) are in schools
(50% in primary school, 42% in junior secondary school,
and 36% in senior secondary school) [32].
The research team will train two teachers per school
(one health teacher and one social teacher) who will in
turn train six school children as peer health educators
(PHEs) with the support from the research team, giving
130 teachers and 390 peer-health educators in total. The
PHEs will be responsible for implementing a range of ac-
tivities designed to raise awareness about diagnosing mal-
aria using RDTs and that ACTs are the recommended
antimalarial. Activities including dramas, songs, card
games, and health talks, will be undertaken duringmorning assembly, Parent Teachers Association (PTA)
meetings, and at some school events such as prize-giving
days. In addition, teachers and PHEs are supported to
hold their own school malaria events involving parents,
guardians, and other community members that will be
invited to participate in card games, dramas, songs, and
health talks. Handbills, posters, T-shirts, and baseball caps
promoting the school-based intervention will be distribu-
ted at all events. A short description of each type of activ-
ity is given below.
 A short drama will emphasize the rational use of
antimalarial drugs, including the use of ACTs and
the need to test before treatment. The school
children will perform the drama in school. Each
drama session will last for no more than 15 minutes.
Transportation and costumes will be procured by
the research team and T-shirts will be given to the
drama team with the inscription ‘REACT AGAINST
MALARIA’. A drama sketch has been developed by
a local theater artist for training purposes.
 The research team provides teachers with malaria
songs that they in turn will communicate to PHEs.
The songs will emphasize the need to go for a test
when one has a fever or headache and to take an
ACT when the test is positive. Three different songs
have been composed by local artists. Each of the
songs will last for 5 minutes and contain up to four
verses.
 A card game will be introduced to school children
and community members, which teaches and
reinforces components of appropriate treatment of
malaria. Between four and six participants take turns
in collecting cards and achieve a point when they
present three cards that show a patient has received
treatment in line with guidelines. This can be
achieved by presenting a ‘patient with fever’ card
accompanied by a ‘RDT positive’ card and an ‘ACT’
card, or alternatively by presenting a ‘patient with
fever’ card accompanied with an ‘RDT negative’ card
and a ‘further investigation’ card. The game ends
when a participant has treated five patients in line
with the guidelines and scored 5 points.
 Health talks will be given by the PHEs to the
schoolchildren in selected primary and secondary
schools in the intervention clusters. The health talk
will include issues about appropriate treatment of
malaria including the need to have a malaria test
before taking treatment, asking for ACTs when the
malaria test is positive, not asking for an antimalarial
when the malaria test is negative, not to take
monotherapies, and and the importance of sharing
the knowledge they have gained with other
members of their households.
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offices, staff common rooms, assembly grounds, and
other strategic places. Handbills will be shared with
community members during malaria events in schools
and also be given to providers at the facilities so they
can distribute to patients who visit the facilities. The
posters will also be displayed at health facilities and at
prominent places in the intervention clusters such as
market places, village squares, and village halls. The key
messages contained in the posters and handbills
include steps towards appropriate treatment of malaria
(that is the need to have a diagnostic test before taking
malaria treatment; people should ask for or receive
ACTs when a test is positive; people should not receive
an antimalarial when a test is negative; and people
should not receive monotherapy).
The research team will conduct support visits to each
school every month during the implementation phase and
the subsequent evaluation phase to guide and encourage
teachers and PHEs involved in the school-based malaria
education. During these visits they will check to see if tea-
chers have created PHEs and if possible attend a meeting
of the PHEs. Where PHEs have not been set up, the re-
search team will encourage and support their establish-
ment. Also during support visits, the team will review
preparations for the school malaria event and attempt to
observe the drama group rehearsals and health talk pre-
sentations, and check if posters have been displayed.
Objectives
The primary objectives are as follows:
1. To evaluate the effectiveness and cost-effectiveness
of the provider intervention compared to expected
standard practice. Where:(i) expected standard practice is defined as facilities
having access to RDTs and have been shown how
to use them
(ii)provider intervention is defined as provider
training and supervision on malaria diagnosis and
treatment in a setting in which facilities can offer
rapid diagnostic testing (including a
demonstration on how to use RDTs);
2. To evaluate the effectiveness and cost-effectiveness
of the combined provider intervention and the
school-based intervention to expected standard
practice; and
3. To evaluate the effectiveness and cost-effectiveness of
the combined provider intervention and the school-
based intervention compared to the provider
intervention alone.Secondary objectives include:
1. To describe the process of implementing the
interventions including participant assessment of the
training received by providers and teachers;
2. To evaluate the impact of interventions on provider
knowledge and ability to test and appropriately treat
patients with suspected malaria;
3. To evaluate the impact of interventions on
community knowledge of and preference for malaria
diagnosis and treatment;
4. To evaluate patient satisfaction with the quality of
care received at the health facility;
5. To calculate the economic and financial costs of the
interventions;
6. To assess whether the effectiveness and cost-
effectiveness of the interventions vary according to
urban/rural residence or the socioeconomic status of
the patient.
Hypotheses
1. The provider intervention will be more effective and
cost-effective in improving the treatment and
diagnosis of malaria compared to what is expected
to be standard practice.
The components of the provider intervention will lead
to the delivery of more appropriate treatment.
Specifically, the provider intervention will improve the
competency of providers to deliver treatment to febrile
patients based on the result of a malaria test.
2 The combined provider and school-based
intervention will be more effective but also more
costly compared to expected standard practice and
the provider intervention alone.
The school-based intervention will have a direct effect
by improving the knowledge of community members in
terms of why they should be tested, the availability of
testing, and that ACTs are recommended for confirmed
cases of malaria. We expect that these changes in
knowledge will also affect what patients ask for when
they attend health facilities, and are therefore more
likely to ask for a test and/or ask for an ACT.
The school-based component of the community
intervention will also have an indirect positive effect
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aware of the school-based intervention, they will
know that patients have been made aware that
malaria testing is available and recommended, and
that malaria should be treated with an ACT. It is
hypothesized that the providers will then feel more
comfortable suggesting that patients are tested and
confident in recommending that confirmed cases
should be given an ACT.
While the combined interventions are predicted to
have a positive synergistic effect, the combined costs of
a school-based intervention in both primary and
secondary schools and of provider training workshops
that involve supervisory visits are likely to be greater
than those associated with expected standard practice
or the provider intervention alone.
The relationship between the study hypotheses and
outcomes are summarized in Figure 1.Figure 1 Effect of interventions on the treatment received by patientOutcomes
Primary outcome
The primary outcome is the proportion of patients
attending facilities that report a fever or suspected mal-
aria and receive treatment according to malaria guide-
lines. The corresponding measure of cost-effectiveness is
the cost per febrile patient that receives treatment
according to the malaria guidelines.
Treatment according to the malaria guidelines is a
composite endpoint requiring that: febrile patients
should be tested for malaria, using either microscopy or
an RDT; the patient should receive an ACT if s/he has a
positive malaria test result; and the patient should not
receive an antimalarial if s/he has a negative malaria test
result.
The outcome measure is summarized in Figure 2.
Secondary outcomes
Secondary outcomes include the following:s.
Figure 2 Primary outcome measure.
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tested for malaria; proportion of febrile patients
receiving an antimalarial that receive an ACT;
proportion of febrile patients receiving an ACT that
receive the correct dose for their age; proportion of
febrile patients receiving an ACT that accurately
report how to take the medicine; proportion of
febrile patients that report they are satisfied with the
care received; proportion of patients attending a
health facility that report a school malaria event
took place in their community.
2. Providers: proportion of providers that report they
were satisfied with the training received; proportion
of providers that report febrile patients should be
tested for malaria; proportion of providers that know
how to identify positive, negative, and invalid
malaria RDT results; proportion of providers that
know ACT should be given if the malaria test is
positive and that an antimalarial should not be given
if the malaria test is negative; proportion of
providers that know the correct dose of the first line
ACT in an adult and in a child aged 2 years.
3. Community members: proportion of individuals that
were aware of a school malaria event; proportion of
individuals that report they had attended school
malaria event; proportion of individuals that report
febrile patients should be tested for malaria;
proportion of individuals that know ACT is the
recommended treatment for malaria; proportion of
individuals that know ACT should be given if the
malaria test is positive and that an antimalarial
should not be given if the malaria test is negative.4. Costs: total cost of the provider and school-based
interventions; mean cost per provider trained under
the provider intervention; mean cost per school
participating in the school-based intervention.
Secondary outcomes related to patients will also be
reported in terms of their urban/rural residence and
socioeconomic status.
Evaluation design
The evaluation of the interventions will use data col-
lected in a patient exit survey, a register of malaria tests
conducted by the provider during patient consultations,
a provider survey, documentation of the intervention
process, a household survey, and costing of the interven-
tion activities. The patient exit survey will be adminis-
tered before the provider survey to ensure that the
treatment received by patients is not influenced by the
content of the provider questionnaire. Each of these re-
search instruments is described below.
Patient exit survey
The primary outcome will be measured through an
interviewer-administered patient exit survey. Data col-
lection will commence 3 months after the intervention
has been implemented. The three-month lag before data
collection is to ensure that the effect measure reflects
treatment practices in the medium term. In the short
term it is recognized that it is possible that the effect is
overstated because providers change practices initially
but revert to past behaviors over time, or that the effect
is understated because it takes time for the training to
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to learn from the experience of the early-adopters.
The research team will recruit field workers and provide
training over 1 week on all aspects of data collection related
to the patient exit survey. The training will include a prac-
tical assessment of their ability to provide information to
respondents about the survey, obtain consent and adminis-
ter the questionnaire. The research team will supervise the
field workers and will accompany the field worker at the
start of data collection to obtain consent from the head of
the facility and ensure the fieldworker adheres to the stand-
ard operating procedures. Supervisory visits to monitor the
performance of the field workers will take place at least
once each week during the data collection period.
The patient exit questionnaire is designed to collect
information about the patient’s experience of seeking
treatment and has been piloted at selected facilities in
the study site. The questionnaire contains the following
10 modules:
A. Background Information, Consent and Screening
Questions
B. Details of the Respondent and/or Patient
C. Reasons for attendance
D. Consultation and diagnosis
E. Treatment prescribed and received
F. Patient satisfaction and knowledge of malaria
G. Costs of seeking treatment
H. Household characteristics
I. Malaria test completed by the research team (in
sub-sample of patients)
J. Malaria test completed by providers (from register
of malaria tests at facility)
Register of malaria tests conducted
The patient exit questionnaire will be supplemented by a
register of malaria tests at each participating health facil-
ity because patients may not always know if they were
tested for malaria and the result of the malaria test.
With consent from the head of the facility, providers re-
sponsible for conducting malaria tests will be asked to
keep a register of all malaria tests undertaken. The fol-
lowing data will be collected: details of the patient, avail-
ability of microscopy and RDT, method of test
conducted, test result and the provider that conducted
the test. At each facility the field workers will collect the
register of malaria tests at least once each week and will
use the patient’s name, gender, age, and date of visit to
identify the patients that completed the survey and rec-
ord the details in Section J of the questionnaire.
Provider survey
The research team will administer a survey to all provi-
ders responsible for the diagnosis and treatment ofsuspected cases of malaria. Providers are eligible to par-
ticipate if their responsibilities include any of the follow-
ing activities: taking patient signs and symptoms,
undertaking diagnostic tests, prescribing or dispensing
medication.
The provider survey has been designed to collect
data on the providers’ characteristics, knowledge and
preferences for diagnosing and treating malaria and
details of the resources available at the health facility.
The survey will be piloted with providers at facilities
that are not participating in the study. The question-
naire contains the following modules (of which A and
B are completed by all providers and C to G are com-
pleted once for each facility):
A. Background information, consent and screening
questions
B. Provider characteristics and treatment practices
C. Details of the health facility
D. Management and procurement of drugs
E. Availability of RDTs
F. Availability of antimalarial drugs
G. List of all providers that are involved in diagnosis or
treatment
Documentation of the implementation of the intervention
The process of distributing the RDTs to health facilities
will be monitored and any problems with the procedures
for replenishing RDT stocks will be documented. Simi-
larly, the occurrence of stock-outs of ACTs in all the fa-
cilities will be monitored.
Details of all participants attending the provider train-
ing on malaria diagnosis and treatment will be recorded.
Participants will undertake a pre- and post-training test
to determine the impact of the course on their know-
ledge of malaria diagnosis and treatment. In addition, all
participants will be invited to complete the training
evaluation, which assesses the content and delivery of
the training course. The trainers will also complete a
form to record any challenges faced in running the
training workshop.
For the school-based intervention, details of all partici-
pants attending the training course will be recorded, and
copies will be taken of the action plans developed during
the training course. All course participants will be asked
to complete an evaluation form and assess the content
and delivery of the training course. All participants will
also be asked to complete a pre- and post-training test
which will indicate the effect of the course on partici-
pant’s knowledge of malaria and peer health education.
The extent to which the school-based intervention is
implemented by teachers in schools will be recorded by
a representative from the research team who visits the
school once the training is complete to provide support
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tion. During this visit the representative will note pro-
gress (with reference to the action plan developed by the
teachers). The representative will also attend the school-
based malaria event and record the activities held and
attendance rate.
Implementation of the interventions is expected to vary
by provider and/or by school thereby reflecting what
would happen if the government were to roll out the
interventions in a ‘real life’ setting. Data on the implemen-
tation process will reveal factors affecting compliance.Household survey
A household survey will be undertaken to collect data
on the community knowledge of malaria diagnosis and
treatment, and on experience of treatment seeking for
febrile illness that had been experienced in the previous
2 weeks. This will provide insight into the reach of the
school-based activities and the effect of the intervention
on the knowledge and preferences of community mem-
bers. Data collection will commence 3 months after the
intervention has been implemented. As mentioned earl-
ier, the three-month lag in the data collection is to en-
sure that the effect measured reflects treatment practices
in the medium-term.
The household questionnaire will be completed by one
individual per household, usually the primary caregiver.
Modules B and C will be asked of several individuals in
each household to consider whether there are differ-
ences in the knowledge of malaria diagnosis and treat-
ment by respondent characteristics.
The household survey contains the following modules:
A. Background information
B. Household members
C. Household knowledge of malaria and malaria
treatment (including attendance at school malaria
event)
D. Treatment seeking of each household member with
a fever in the past 2 weeks (if applicable)
E. Household characteristicsCosts
The direct and indirect costs of each phase of the inter-
ventions (that is development, implementation, upkeep)
will be assessed from both a provider and societal perspec-
tive using standard economic evaluation methodologies
[39]. Cost data will primarily be estimated from health fa-
cility records, project financial accounts, and from the
provider and patient exit surveys. An estimate of health-
care savings will also be included and subtracted from
costs using the Shillcutt model [22].Quality assurance
Data collection and management
There is a quality assurance officer responsible for ensur-
ing all implementation and evaluation activities adhere to
standard operating procedures. Quality assurance will in-
clude monitoring the process of obtaining consent, data
collection, transfer of completed survey instruments, data
management, and the secure storage of study materials. In
addition, field supervisors will monitor the survey admin-
istration undertaken by field workers and make frequent
visits (at least once a week) to assess the quality of data
collection and review completed questionnaires.
Only authorized staff with appropriate training will have
access to the databases to perform data entry. All data-
bases will be password protected. Each data form will be
entered by two data entry clerks in a database of the same
structure using two different computers. Entries will be
compared for discrepancies using the Epi info 2000 data
compare utility. Any discrepancies will be corrected by
crosschecking against the corresponding original ques-
tionnaire. Checks (validation rules) will be implemented
in different fields of the database. Data will also be queried
electronically to ensure the correct data are entered under
the correct variables for each section of the form/ques-
tionnaire. A log of all data changes will be kept. Question-
naires will be kept in a locked filing cabinet.
Independent verification of malaria tests conducted and
test results
Reliance on providers’ register of malaria tests con-
ducted and their interpretation of the test result may be
a risk for data quality. For example, we are dependent
on the providers’ skills in conducting and interpreting
the test results and the accuracy of their record-keeping.
We will examine the accuracy of the register of malaria
tests by comparing the patient reported data on whether
they had a test with the register. We will also independ-
ently conduct RDT tests in a subsample of 5% of
patients on exit that reported they were tested for mal-
aria to determine the degree of consistency between the
test result recorded by the provider and the test result
conducted by the fieldworker. Quality assurance of the
RDTs is beyond the scope of the study.
Sample size
Patient exit survey
Sample size calculations are based on the primary out-
come; the proportion of febrile patients receiving treat-
ment as recommended in malaria treatment guidelines.
Based on provider adherence to test results in our forma-
tive research and assumptions about the incentives of pro-
viders in private facilities we expect that this will be 10%
in the control arm (basic provider training) with a coeffi-
cient of variation within stratum of 0.35. Using methods
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arm with a harmonic mean of 50 febrile patients per clus-
ter will be needed to detect a 15% incremental increase
between the study arms, from 10% to 25% for the provider
intervention (arm 2), and from 25% to 40% with the
addition of the school intervention (arm 3) with 80%
power at a 5% significance level.
Provider survey
The sample size calculations for the provider survey gives
the anticipated level of precision for calculating the pro-
portion of providers that know the treatment guidelines
(that is report that parasitological testing is recommended
and that ACTs are for confirmed cases of malaria). Based
on logistics and costs a total of 138 facilities (an average of
three to four facilities per cluster) will be included in the
study. From the baseline survey we know that there are
three to four workers per facility hence we can expect on
average 138 workers to be surveyed per arm. Assuming
that the estimate of the primary outcome is 50% in the
control arm and 75% in each of the intervention arms,
and an intra-correlation coefficient (ICC) of 0.25, this
allows us to estimate the true primary outcome with
± 14.5% precision in the control arm and±12.5% precision
in each of the intervention arms.
Household survey
\Sample size calculation for the household survey is
based on the number of clusters identified for the pa-
tient exit survey (that is 14 clusters per arm) and gives
the anticipated level of precision for calculating the pri-
mary outcome; the proportion of individuals surveyed
that know that parasitological testing is recommended
and know that ACTs are the recommended treatment
for confirmed cases. Assuming that the estimate of the
primary outcome is 10% among those attending facilities
in Arm 1 (expected standard practice), 20% for those liv-
ing in clusters receiving the provider intervention (Arm
2), and 50% in the combined provider and school inter-
vention clusters (Arm 3), that one individual per house-
hold will be sampled and the intra class-correlation (ρ)
will be 0.2, we will survey 25 per cluster (350 per arm).
This allows us to estimate the true primary outcome
with ±7.9% precision in Arm 1, ±10.5% precision in Arm
2, and ±13.1% precision in Arm 3.
Randomization
With cluster randomized trials there is an increased
chance that the study arms are unbalanced with respect
to known and unknown potential confounders, and
therefore undermines the credibility of the trial results.
Stratified randomization will reduce some of the imbal-
ance in factors known to be correlated with the study
outcome and the study site. However, this does notenable us to balance on type of facility and the number
of facilities which were also expected to be important
correlates of the primary outcome. Hence, a system of
constrained randomization [41,42] will also be used to
allocate communities to the study arms within each
stratum to ensure balance in these factors.
The validity of the restricted randomization will be
assessed by producing a matrix where the rows and col-
umns represent the clusters and the elements of the
matrix are the proportion of times each pair of clusters
is allocated to the same study arm, that is the probability
that the ith cluster is being allocated to the same inter-
vention group as the jth cluster. The matrix will then be
examined for under- and over-represented pairs that
would highlight any potential causes for concern in the
randomization.
Randomization of the clusters will be performed by
the study statistician after informed consent has been
sought from the heads of the facilities, community
heads, and schools to avoid selection bias. Patients (or
caregivers) and fieldworkers administering the patient
exit survey will be blinded to group assignment. The re-
search team involved in implementing the interventions
and supervising data collection will need to be aware of
which clusters and in turn which facilities and schools
receive the different interventions (Figure 3).
Data analysis
The primary outcome will be compared between each of
the study arms using methods appropriate for cluster
randomized trials. Due to the small number of clusters
per arm analysis based on cluster-level summaries will
be applied. Point estimates of the primary outcome will
be calculated using the weighted average of the cluster
proportions, with the weights provided by the sample
size for each cluster. If the distribution of the summary
measures in each study arm is skewed, a logarithmic
transformation to the proportions will be considered. An
overall estimate of the risk difference will be obtained by
taking a weighted average of the stratum-specific esti-
mates with the weights proportional to the number of
clusters in each stratum since an equal number of clus-
ters have been allocated to the study arms within each
stratum. 95% confidence intervals (CI) will be adjusted
for observed between-cluster variance and formal hy-
pothesis testing will be conducted using stratified t-tests.
Adjustment for covariates, including patient and provider
characteristics and knowledge, contextual factors, and
process factors, will be carried out using a two-stage
process. In the first stage a logistic regression model in-
cluding stratum as a fixed effect and the covariates of
interest, but excluding the intervention effect, will be fit-
ted to calculate cluster-specific expected values. The dif-
ference of observed to expected values will give the
Figure 3 Eligibility, selection, enrolment, and data collection.
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the above methods are carried out with the cluster-level
proportions replaced with the covariate-adjusted residuals.
Secondary outcomes will be analyzed using the methods
described above. To examine whether secondary out-
comes associated with the patient vary according to
urban/rural residence and socioeconomic status methods
appropriate for examining an interaction between the
intervention and the individual-level variable will be ap-
plied [43].
Data will be double entered using Microsoft Access
2007 (Microsoft Inc., Redmond, WA, USA) and analyzed
using STATA version 11.0 (STATA Corporation, College
Station, TX, USA). A full analysis plan will be reviewed
and agreed before the data are analyzed.Cost-effectiveness
Cost-effectiveness ratios will be based on the primary
outcome (that is the cost per case of suspected malaria
that received treatment as recommended in the malaria
guidelines) as well as a range of secondary outcomes in-
cluding changes in provider knowledge. Cost-effective-
ness will be calculated for each comparison and will be
expressed as incremental cost-effectiveness ratios
(ICERs). One-way and multiway sensitivity analysis will
be undertaken to examine the effects of varying uncer-
tain variables on study findings. Costs and effects willbe presented in both discounted and undiscounted
form.
Dissemination
Results from the study will be reported at local, national,
and international levels. At the local and national level,
the Research on the Economics of ACTs (REACT) Project
(http://www.actconsortium.org/pages/project-5.html) will
continue working with the Ministry of Health after the
trial is completed to adapt the most cost-effective inter-
ventions for national use. At the international level, we
also see an opportunity to support the implementation of
the 2010 WHO malaria treatment guidelines which ac-
knowledge the need for provider training alongside the
large-scale deployment of RDTs and ACTs.
Trial status
The trial is ongoing. Patients are still being recruited.
Endnote
aPrices are based on a willingness to pay study under-
taken in Enugu State by Uzochukwu et al. [38].
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